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Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder (1) and the leading genetic 
cause of  infant mortality (2). The major pathological components of  the disease are the selective loss of  spinal 
cord α motor neurons, progressive muscle denervation (3), and skeletal muscle atrophy (4). SMA is caused by 
mutations in the survival motor neuron 1 (SMN1) gene (5). SMN protein is ubiquitously expressed, and com-
plete loss is lethal (6). However, humans have a near-identical centromeric copy of  the SMN1 gene, termed 
SMN2, in which a single nucleotide change (C to T) in exon 7 (7) results in the exclusion of  exon 7 from 
approximately 90% of the mature transcript (8). The resulting protein is unstable and gets rapidly degraded 
(9). Patients can have a varying number of  SMN2 copies, which correlates with disease severity, as each SMN2 
copy retains the ability to produce approximately 10% of functional full-length (FL) protein (10, 11).
The first SMN restoration treatments, Spinraza, Zolgensma, and Evrysdi, have recently been approved 
by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Spinraza 
(12) is an antisense oligonucleotide (ASO) that promotes SMN2 exon 7 inclusion (13) and is administered by 
lumbar puncture, Zolgensma delivers SMN1 cDNA via an adeno-associated virus 9 (14) and is administered 
i.v., and Evrysdi is a small molecule that increases SMN2 exon 7 inclusion and is administered orally (15). 
While these treatments have changed the SMA therapeutic landscape, they unfortunately fall short of  repre-
senting a cure (16–18). There is, therefore, a present need for SMN-independent therapies that could be used 
in combination with SMN restoration treatments to provide a longer-lasting and more effective therapeutic 
management of  SMA pathology in patients (16–18).
Skeletal muscle pathology is a clear contributor to SMA disease manifestation and progression, and 
improving muscle health could have significant benefits for patients (19). Here, we used an in-depth and par-
allel approach combining proteomics, transcriptomics, and the drug perturbational data set Connectivity Map 
(CMap; refs. 20, 21) to identify differentially expressed (DE) transcripts and proteins in skeletal muscle of the 
Spinal muscular atrophy (SMA) is a neuromuscular disorder caused by loss of survival motor neuron 
(SMN) protein. While SMN restoration therapies are beneficial, they are not a cure. We aimed to 
identify potentially novel treatments to alleviate muscle pathology combining transcriptomics, 
proteomics, and perturbational data sets. This revealed potential drug candidates for repurposing in 
SMA. One of the candidates, harmine, was further investigated in cell and animal models, improving 
multiple disease phenotypes, including lifespan, weight, and key molecular networks in skeletal 
muscle. Our work highlights the potential of multiple and parallel data-driven approaches for the 
development of potentially novel treatments for use in combination with SMN restoration therapies.
2
R E S E A R C H  A R T I C L E
JCI Insight 2021;6(13):e149446  https://doi.org/10.1172/jci.insight.149446
severe Taiwanese Smn–/–;SMN2 SMA mice (22) that could potentially be restored by known and available phar-
macological compounds. This strategy uncovered several potential therapeutic candidates, including harmine, 
which was further evaluated in cell and animal models, showing an ability to restore molecular networks and 
improve several disease phenotypes, including lifespan and weight. Our study highlights the tremendous poten-
tial of intersecting disease multiomics with drug perturbational responses to identify therapeutic compounds 
capable of modulating dysfunctional cellular and molecular networks to ameliorate SMA phenotypes.
Results
Early restoration of  SMN in SMA mice restores muscle protein and transcript expression. We first set out to deter-
mine the effect of  early SMN restoration on the proteomic and transcriptomic profiles of  SMA skele-
tal muscle, with the intent to design therapeutic strategies against the genes and proteins that remained 
unchanged. To do so, the severe Taiwanese Smn–/–;SMN2 SMA mouse model (22) received a facial i.v. 
injection at P0 and P2 of  the previously described Pip6a-phosphordiamidate morpholino oligomer (Pip6a-
PMO) or Pip6a-scrambled pharmacological compounds (10 μg/g; ref. 23, 24). Pip6a is a cell-penetrating 
peptide (CPP) conjugated either to an SMN2 exon 7 inclusion-promoting ASO (PMO) or a scrambled ASO 
(23, 24). We have previously reported that administration of  Pip6a-PMO to newborn Smn–/–;SMN2 mice 
led to increased SMN protein levels in numerous tissues, including skeletal muscle, and a concomitant 
40-fold increase in survival (23). We harvested the tibialis anterior (TA) from P2 (presymptomatic) untreated 
Smn–/–;SMN2 and WT mice, P7 (symptomatic) untreated Smn–/–;SMN2 and WT mice, and P7 Pip6a-scram-
bled Smn–/–;SMN2 and Pip6a-PMO–treated Smn–/–;SMN2 mice. TAs were then cut in 2, whereby one half  
was used for transcriptomics (whole-transcript array assay) and the other for proteomics (liquid chroma-
tography–mass spectrometry; LC-MS). Quantitative PCR (qPCR) analysis of  the ratio of  FL SMN2 over 
total SMN2 confirms a significant increase in FL SMN2 expression in P7 Pip6a-PMO–treated Smn–/–;SMN2 
mice compared with age-matched untreated and Pip6a-scrambled–treated Smn–/–;SMN2 mice (Figure 1A).
Despite differences between the transcriptomic and proteomic methodologies, highlighted by hierarchi-
cal clustering and combined Principal Component Analysis (PCA; Supplemental Figure 1; supplemental 
material available online with this article; https://doi.org/10.1172/jci.insight.149446DS1), we were able 
to find clear separation of  experimental groups and agreement between transcriptomic and proteomic pro-
files once the variance attributed to the differences in methodologies was removed (Figure 1B). At P7, we 
observed a clear separation of  Smn–/–;SMN2 and WT samples, where only Pip6a-PMO–treated Smn–/–;SMN2 
mice clustered with WT (Figure 1B and Supplemental Figure 2). We also found that P2 Smn–/–;SMN2 and 
WT samples clustered together (Figure 1B and Supplemental Figure 2), suggesting that overt disease cannot 
be detected in omics readouts at this early stage. In the PCA of  P7 samples only (Figure 1C for transcrip-
tomics and Figure 1D for proteomics), we noted clustering of  P7 Pip6a-PMO–treated Smn–/–;SMN2 mice 
with untreated P7 WT animals, suggesting a significant restoration of  both transcriptomic and proteomic 
expression profiles. Surprisingly, we also detected segregation of  Pip6a-scrambled–treated samples at both 
transcriptomics and proteomics levels, revealing that presence of  the CPP itself  impacted transcription and 
translation (Figure 1, C and D, and Supplemental Table 1). Importantly, both the combined and separate 
analyses of  transcriptomic and proteomic data allowed us to identify a robust SMA disease signature in mus-
cle and a Pip6a-PMO treatment efficacy signature. Indeed, identification of  DE genes and proteins revealed 
that early induction of  FL SMN expression by Pip6a-PMO normalized the expression of  all transcripts 
and all but 11 proteins in the TA of  Smn–/–;SMN2 mice (Tables 1 and 2). Of  note, one of  the proteins that 
remained significantly downregulated is SMN itself  (Table 2), which is in contrast with the complete nor-
malization of  FL SMN2 transcript levels (Figure 1A) and perhaps due to distinct regulation of  SMN RNA 
and protein stability (25, 26) that might be impacted differently during development — in this case, prior to 
Pip6a-PMO–mediated SMN restoration. Nevertheless, this increase is sufficient to rescue the disease pheno-
type, which is aligned with previous reports of  an SMN threshold, whereby a normal phenotype has been 
observed in mice with as little as 30% SMN protein when compared with WT levels (27).
Our in-depth molecular profiling thus demonstrates for the first time, to the best of  our knowledge, that 
increasing FL SMN2 in neonatal SMA mice almost completely normalizes muscle transcripts and proteins, 
highlighting at the molecular level the potential treatment benefits arising from early intervention.
CMap perturbational profiles identify potential novel non-SMN treatments. We used the transcriptomic and 
proteomic profiles of  the Smn–/–;SMN2 mice treated with Pip6a-PMO to find drugs that induced similar tran-
scriptional patterns using the CMap resource (20, 28). Briefly, CMap is a database where gene expression 
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profiles of  human cell lines treated with different drugs are collected, therefore providing a resource for drug 
repurposing studies. Specifically, by selecting drugs that induce gene expression profiles that are inverse (or 
anticorrelated) to disease-associated gene expression profiles, it is possible to identify new candidate ther-
apeutics with the potential to counteract the disease effects under investigation. Thus, we firstly generated 
Figure 1. Restoration of protein and transcript expression in skeletal muscle of SMA mice following early SMN 
restoration treatment. Smn–/–;SMN2 mice received a facial i.v. injection at P0 and P2 of Pip6a-scrambled or Pip6a-
PMO (10 μg/g). The tibialis anterior was harvested from P2 untreated Smn–/–;SMN2 and WT mice; from P7 untreated, 
Pip6a-scrambled-treated, and Pip6a-PMO-treated Smn–/–;SMN2 mice; and from P7 untreated WT mice. (A) Compar-
ison of the ratio of full-length (FL) SMN2 over total SMN2 quantified by qPCR between P7 untreated, Pip6a-scram-
bled-treated, and Pip6a-PMO–treated Smn–/–;SMN2 mice. Data are shown as a scatter plot and are represented as 
mean ± SEM; n = 4 animals per experimental group, 1-way ANOVA followed by a Dunnett’s multiple comparisons test, 
F ratio (F) = 34.88, degrees of freedom (df) = 11, ***P < 0.001. (B) Heatmap of the transcriptomic and proteomic expres-
sion profiles measured by the Pearson correlation between each pair of samples (after the removal of the first principal 
component). (C) First 2 principal components based on transcriptomic profiles of P7 untreated WT mice, untreated 
Smn–/–;SMN2 mice, Pip6a-PMO–treated Smn–/–;SMN2 mice, and Pip6a-scrambled Smn–/–;SMN2 mice. (D) First 2 princi-
pal components based on proteomic profiles of P7 untreated WT mice, untreated Smn–/–;SMN2 mice, Pip6a- 
PMO–treated Smn–/–;SMN2 mice, and Pip6a-scrambled Smn–/–;SMN2 mice.
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a filtered and reversed disease signature for both transcriptomics and proteomics data by excluding the tran-
scripts and proteins restored by Pip6a-scrambled (Pip6a-scrambled–treated Smn–/–;SMN2 versus untreated 
WT) from the overlap between disease (untreated Smn–/–;SMN2 versus untreated WT) and Pip6a-PMO 
(Pip6a-PMO treated Smn–/–;SMN2 versus untreated Smn–/–;SMN2) (Figure 2A). These filtered sets of  tran-
scripts and proteins show a significant overlap between different data types (Supplemental Figure 3) and 
a greater similarity at the level of  enriched pathways when compared with nonfiltered sets (Figure 2B). A 
complete list of  enriched gene ontology (GO) biological processes across all tested comparisons (transcripts 
and proteins) is compiled in Supplemental Table 2.
The top 10 pharmacological compounds from CMap showed a reversed pattern of  expression for the 
disease signature and a similar expression pattern to that observed with Pip6a-PMO treatment, listed in Table 
3. Importantly, a subset of  these drugs — namely, salbutamol (29) and alsterpaullone (30) — have already 
been considered for SMA treatment, highlighting the capability of  this analytic approach to identify relevant 
therapeutic options for SMA.
Our bioinformatic analysis, therefore, revealed that the Pip6a peptide itself  led to several molecular changes 
in skeletal muscle, underscoring the importance of including such controls to avoid erroneous interpretations. 
Here, the generation of filtered data sets that excluded proteins and transcripts modulated by the Pip6a peptide 
only, allowed us to confidently identify transcripts, proteins, and biological pathways selectively restored by 
increased SMN levels and relevant candidate drugs predicted to have similar activities. Thus, our strategy of  
combining transcriptomics, proteomics, and drug perturbational data sets has resulted in the generation of a list 
of several pharmacological compounds with the potential to restore muscle health in SMA.
Harmine displays predicted activity on candidate reporter genes in a cell- and dose-dependent manner. To further 
validate our combined bioinformatics and drug repurposing approach, we chose to evaluate the potential 
of  harmine (chemically akin to harmol), which is a drug that has been identified by its CMap profile but 
not previously evaluated for SMA and which is present in several proteomic and transcriptomic signatures 
(Table 3). Harmine is an alkaloid isolated from the seeds of  Peganum harmala, traditionally used for ritual 
and medicinal preparations (31, 32). Harmine has also demonstrated therapeutic benefits (33) in animal 
models of  the motor neuron disease amyotrophic lateral sclerosis (ALS) (34) and the muscle disorder myo-
tonic dystrophy type 1 (DM1; ref. 35).
Table 1. Number of differentially expressed (DE) transcripts and proteins between experimental groups.


















Transcripts 5698 4959 4539 1225 0 702 4986 2473 0
Proteins 715 2694 1606 258 0 430 902 367 0
Intersect 253 1213 653 87 0 137 397 214 0
Jaccard Index 4.11% 18.84% 11.89% 6.23% 0% 13.77% 7.2% 8.15% 0%
DE–transcript-only 88.39% 58.17% 70.76% 81.52% 0% 56.78% 83.6% 86.02% 0%
DE–protein-only 7.50% 23.00% 17.35% 12.25% 0% 29.45% 9.2% 5.83% 0%


















Transcripts 5343 4755 3627 787 0 1166 4956 1688 0
Proteins 2659 640 402 509 11 178 4400 883 0
Intersect 1302 247 144 155 0 60 1604 252 0
Jaccard Index 19.43% 4.80% 3.71% 13.58% 0% 4.67% 20.7% 10.87% 0%
DE–transcript-only 60.31% 87.57% 89.65% 55.39% 0% 86.14% 43.2% 61.92% 0%
DE–protein-only 20.25% 7.63% 6.64% 31.03% 0% 9.19% 36.1% 27.21% 0%
FDR < 0.05 was used for both protein and transcript data. Transcripts and proteins were considered DE if at least 1 of their corresponding transcripts/
proteins had an FDR < 0.05. The percentages are relative to the total of both DE transcripts and proteins per experimental group. P7WT, P7 untreated WT; 
P7SMA, P7 untreated Smn–/–;SMN2; P7Pip6a, P7 Pip6a-PMO–treated Smn–/–;SMN2; P7Scrambled, P7 Pip6a-scrambled–treated Smn–/–;SMN2; P2 SMA, P2 
untreated Smn–/–;SMN2; P2 WT, P2 untreated WT.
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We firstly evaluated the mRNA expression of  the transcripts and proteins predicted to be dysregulated 
by the transcriptomics and proteomics data and to be normalized by harmine through the CMap analysis. 
We indeed confirmed by qPCR analysis that the genes snRNP U4/U6.U5 subunit 27 (Snrnp27), glutami-
nase (Gls), assembly factor for spindle microtubules (Aspm), and minichromosome maintenance complex 
component 2 (Mcm2) are significantly downregulated (Figure 3A), while caseinolytic mitochondrial matrix 
peptidase chaperone subunit X (Clpx), protein phosphatase, Mg2+/Mn2+-dependent 1B (Ppm1b), transducer 
of  ERBB2, 2 (Tob2), and cyclin-dependent kinase inhibitor 1A (Cdkn1a) are significantly upregulated (Fig-
ure 3B) in the TA of  P7 Smn–/–;SMN2 mice compared with WT animals. We then evaluated the ability of  
harmine to impact the expression of  these genes by treating C2C12 myoblasts, NSC-34 neuronal-like cells, 
SMA patient fibroblasts, and control fibroblasts with 25, 35, and 50 μM of the drug for 48 hours. Our bio-
informatic analysis predicted that harmine would increase the expression of  Snrnp27, Gls, Aspm, and Mcm2, 
and we observed an increased expression of  these genes, albeit in a cell- and dose-dependent manner (Figure 
4, A–D). Indeed, some cell types displayed a decreased expression of  the candidate reporter genes (e.g., 
Aspm in SMA patient fibroblasts; Figure 4C), and some cell types demonstrated an increased expression 
only at a specific concentration of  the drug (e.g., Gls in NSC-34s; Figure 4B). Similar results were obtained 
when evaluating the expression of  Clpx, Ppm1b, Tob2, and Cdkn1a — genes predicted to be downregulated 
by harmine (Figure 5, A–D). For the most part, harmine decreased the expression of  these genes, with some 
exceptions where expression was in fact increased (e.g., Cdkn1a in C2C12s; Figure 5D) or decreased only 
at certain doses (e.g., Tob2 in SMA patient fibroblasts; Figure 5C). Our observed cell- and dose-dependent 
pharmacological activity of  harmine most likely reflects that the CMap resource is based on data from 
human cancer cell lines (20, 28). In addition, harmine displayed inhibitory effects on proliferation and via-
bility at the higher doses in C2C12s and NSC-34s (Supplemental Figure 4), which perhaps influenced the 
differential effects of  low and high concentrations in some cell types.
We were thus able to demonstrate the strength of  our combined bioinformatics and drug repurposing 
approach by selecting harmine for additional proof-of-concept investigations. Indeed, we confirmed the pre-
dicted dysregulation of  several candidate reporter genes in skeletal muscle of  symptomatic SMA mice and 
observed a cell- and concentration-dependent modulation of  their expression by harmine.
Administration of  harmine to SMA mice ameliorates disease phenotypes. To further evaluate the potential ther-
apeutic effects of  harmine in vivo, we administered it daily to Smn–/–;SMN2 mice and Smn+/–;SMN2 control 
littermates by gavage (10 mg/kg diluted in 0.9% saline) starting at P0. The 10 mg/kg dose was chosen based 
on its previous demonstrations of  activity and safety in rodents (36). We first evaluated the effects of  harmine 
on the expression of  the candidate reporter genes predicted to be restored by harmine. Of the genes predicted 
to be upregulated by harmine (Snrnp27, Gls, Aspm, and Mcm2), daily harmine administration increased the 
expression of  Snrnp27 in both Smn–/–;SMN2 SMA mice and Smn+/–;SMN2 control littermates and of Aspm 
and Mcm2 in SMA muscle only, compared with untreated cohorts (Figure 6A). Of the genes predicted to be 
downregulated by harmine (Clpx, Ppm1b, Cdkn1a, and Tob2), harmine only reduced the expression of Tob2 in 
Table 2. Proteins downregulated in P7 Pip6a-PMO-treated Smn–/–;SMN2 mice compared with P7 
untreated WT mice.
Proteins downregulated in Pip6a-PMO-treated Smn–/–; 
SMN2 mice versus WT mice FDR
Immunoglobulin κ variable 4–53 0.00045048
Immunoglobulin heavy variable 3–5 0.002948104
Immunoglobulin κ variable 8–28 0.003677276
TAP binding protein 0.020730142
Immunoglobulin κ constant 0.022371166
Survival motor neuron 0.022371166
Immunoglobulin heavy variable 1–81 0.023766096
Immunoglobulin κ variable 10–95 0.026434314
Immunoglobulin κ variable 8–19 0.02731649
Tap1 transporter 1, ATP-binding cassette, subfamily B 0.02731649
Immunoglobulin heavy constant γ 1 0.045336254
Proteins were considered downregulated if FDR < 0.05.
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Figure 2. Identification of disease signal reversed by treatment with Pip6a-PMO by removing the effect of Pip6a scrambled at transcriptomic and proteom-
ic levels. (A) Venn diagrams show the number of transcripts (top) and proteins (bottom) differentially expressed (DE) between untreated Smn–/–;SMN2 and 
untreated WT mice, reversed by treatment with Pip6a-PMO and not DE between Pip6a-scrambled–treated Smn–/–;SMN2 mice and untreated WT animals. 
Filtered signatures were named according to the increase (up) or decrease (down) expression in untreated Smn–/–;SMN2 mice compared with untreated WT 
animals and are highlighted in the green area of the Venn diagrams. (B) Set of enriched gene ontology (GO) biological processes that show similarity across com-
parisons. GO enrichment analysis was performed separately for transcripts and proteins that were DE between untreated Smn–/–;SMN2 and untreated WT mice 
(blue), DE between Pip6a-PMO-treated Smn–/–;SMN2 and untreated Smn–/–;SMN2 mice (purple), and part of the filtered signatures described in A (green).
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SMA mice compared with untreated animals (Figure 6B). Of note, while the Smn+/–;SMN2 mice are healthy 
littermates in terms of  lifespan and reproductive abilities, they nevertheless have reduced levels of  Smn, which 
in itself  has been demonstrated to impact certain phenotypic features (e.g., tail and ear necrosis, metabolism, 
gene expression; refs. 22, 37). As such, comparisons were performed between untreated and harmine-treated 
animals of  the same genotype, allowing us to determine if  the effects were SMA dependent or SMA indepen-
dent, without the addition of  a potential compounding factor.
We next assessed the effect of  harmine on disease progression and found a significant increase in sur-
vival of  harmine-treated Smn–/–;SMN2 mice compared with untreated Smn–/–;SMN2 animals (Figure 7A). 
Harmine administration also improved weights of  treated Smn–/–;SMN2 mice compared with untreated 
Smn–/–;SMN2 animals (Figure 7B), while it did not impact the weights of  Smn+/–;SMN2 control littermates 
(Figure 7C). An intermediate SMA mouse model, termed Smn2B/– (27), was also treated with harmine. 
Harmine administration to Smn2B/– mice similarly resulted in a significant increase in survival compared 
with untreated Smn2B/– animals (Figure 7D), albeit to a lesser extent, most likely due to the fact that the 
treated animals developed tremors and needed to be culled. Tremors have indeed been reported in ani-
mal studies of  long-term harmine administration (38–40). Nevertheless, harmine significantly increased 
the weights of  treated Smn2B/– mice compared with untreated Smn2B/– animals (Figure 7E). Interestingly, 
harmine also had a small but significant impact on the weights of  treated Smn2B/+ control littermates com-
pared with untreated Smn2B/+ animals (Figure 7F).
Given that harmine was chosen to target molecular effectors in muscle, we measured the myofiber size 
in the TAs from P7 untreated and harmine-treated Smn–/–;SMN2 and Smn+/–;SMN2 mice. We observed an 
increased proportion of  larger myofibers in harmine-treated Smn–/–;SMN2 mice compared with untreated 
Smn–/–;SMN2 animals (Figure 8A).
Harmine has also been reported to increase the expression of the neuroprotective glutamate transporter 1 
(GLT-1; refs. 41, 42); thus, we assessed GLT-1 protein levels in P7 spinal cords from untreated and harmine-treat-
ed Smn–/–;SMN2 and Smn+/–;SMN2 mice. We found that harmine administration significantly increased GLT-1 
expression in treated Smn–/–;SMN2 mice compared with untreated animals, while having no impact in Smn+/–
;SMN2 healthy controls (Figure 8B and Supplemental Figure 5), suggesting an SMA-dependent effect.
Table 3. Top 10 pharmacological compounds identified by CMap analysis based on 3 expression 
signatures for both the transcriptomic data and proteomic data.





























































ASignature 1: Differently expressed between untreated P7 Smn–/–;SMN2 and WT mice. BSignature 2: Differentially 
expressed between untreated P7 Smn–/–;SMN2 mice and Pip6a-PMO-treated Smn–/–;SMN2 mice. CSignature 3: 
Differentially expressed between untreated P7 Smn–/–;SMN2 mice and Pip6a-PMO-treated Smn–/–;SMN2 mice, except 
those genes differentially expressed between P7-scrambled-treated Smn–/–;SMN2 mice and untreated Smn–/–;SMN2 mice.
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Finally, given the reported neuroprotective activities of  harmine (43), we proceeded to evaluate motor 
neuron loss in lumbar spinal cords of  untreated and harmine-treated P7 Smn–/–;SMN2 animals (Figure 8C). 
We observed that daily harmine administration significantly increased the number of  motor neurons per ven-
tral horn area in SMA mice, restoring it to the average number found in untreated and treated Smn+/–;SMN2 
healthy littermates (Figure 8C), further supporting a CNS-dependent effect of  harmine.
We, thus, have demonstrated that treating SMA mice with harmine significantly improves multiple 
molecular and pathological phenotypes in both skeletal muscle and the spinal cord.
Harmine administration restores gene expression in muscle of  SMA mice. To systematically explore the effects of  
harmine in SMA muscle and further validate our combined bioinformatics and drug repurposing approach, we 
performed RNA sequencing (RNA-seq) on TAs from P7 untreated and harmine-treated Smn–/–;SMN2 and WT 
mice. A total of 15,523 protein coding genes were identified across all samples. We found that harmine signifi-
cantly reversed 1256 genes that are DE between Smn–/–;SMN2 mice and WT animals (Figure 9A). Interestingly, 
harmine treatment in WT animals influenced the expression of substantially fewer genes than in Smn–/–;SMN2 
mice (Figure 9B), showing a high specificity toward pathways dysregulated in Smn–/–;SMN2 mice, such as 
muscle phenotypes, lipid metabolism, and glucose metabolism (Figure 9C) (44–46). In agreement with the 
incomplete rescue of disease phenotypes in SMA mice, harmine treatment did not restore all DE genes (Figure 
9B) or pathways (Figure 9C) such as muscle cell development and angiogenesis (47, 48). A complete list of  
enriched GO biological processes for the DE genes in each comparison is provided in Supplemental Table 3.
Considering the role of  SMN in regulating RNA splicing (49), we examined whether harmine restored 
splicing alterations observed following loss of  Smn. From a total of  81,011 distinct transcripts, 84 were found 
Figure 3. Harmine target genes, as predicted by CMap analyses, are aberrantly expressed in SMA muscle. (A) qPCR analysis of genes predicted to be 
significantly downregulated (Snrnp27, Gls, Aspm, and Mcm2) in the TA of untreated P7 SMA Smn–/–;SMN2 and WT mice. Data are shown as a scatter 
plot and are represented as mean ± SEM; n = 4 animals per experimental group, unpaired t test, df = 6 for all, P = 0.041 (Snrnp27), P = 0.0019 (Gls), P = 
0.0001 (Aspm), P < 0.0001 (Mcm2). (B) qPCR analysis of genes predicted to be upregulated (Clpx, Ppm1b, Tob2, and Cdkn1a) in the TA of untreated P7 SMA 
Smn–/–;SMN2 and WT mice. Data are shown as a scatter plot and are represented as mean ± SEM; n = 4 animals per experimental group, unpaired t test,  
df = 6 for all except Ppm1b, where df = 5; P < 0.0001 (Clpx), P = 0.0076 (Ppm1b), P = 0.0012 (Tob2), P < 0.0001 (Cdkn1a).
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to be dysregulated in the disease model (Smn–/–;SMN2 versus WT), of  which only 1 was found to be reversed 
by harmine treatment — namely, DNA methyltransferase 3 β (Dnmt3b).
Thus, our RNA-seq analysis demonstrates that harmine reverses a large number of  molecular pathologies 
in skeletal muscle of  SMA mice beyond the selected candidate reporter genes, with a more prominent effect 
on overall expression than alternative splicing.
Harmine restores multiple, but not all, molecular networks disturbed in muscle of  Smn–/–;SMN2 mice. To further 
assess the restorative effects of  harmine at a molecular level, we built a gene functional network from the top 
500 DE genes using functional relationships defined by a phenotypic linkage network that links genes together 
that are likely to influence similar phenotypes (50). Louvain clustering of  this network identified 6 mod-
ules of  interconnected genes disturbed in muscle of  Smn–/–;SMN2 mice (Supplemental Figure 6), of  which 
3 (M1, M2, and M5) were fully restored and 1 (M4) was partially restored by harmine treatment (Figure 
10A). Enrichment analysis in mouse phenotypes highlighted several pathways known to be involved in SMA, 
such as lipid and glucose metabolism (44, 46), as well as muscle fiber morphology and contraction (refs. 45, 
47; Figure 10B), providing potential molecular explanations for the improved phenotypes in harmine-treated 
SMA mice and a similarity to the pathways associated with Pip6a-PMO treatment (Figure 2B). A tissue 
enrichment analysis on GTEx gene expression data confirmed the effect of  harmine upon muscle-specific 
Figure 4. Harmine, as predicted by CMap analyses, is able to reverse the expression of genes significantly downregulated in SMA muscle in several cel-
lular models. (A–D) C2C12, NSC-34, SMA patient fibroblasts, and control fibroblasts were treated with 25, 35, or 50 μM of harmine for 48 hours. Expression 
of Snrnp27 (A), Gls (B), Aspm (C), and Mcm2 (D) was assessed by qPCR and compared with untreated cells. Data are shown as a scatter plot and are repre-
sented as mean ± SEM; n = 3 independent wells, 2-way ANOVA followed by uncorrected Fisher’s least significant difference (LSD), F = 20.20 (Snrnp27), F = 
90.95 (Gls), F = 14.16 (Aspm), F = 42.61 (Mcm2), df = 32 for all, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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genes (Supplemental Figure 7). Through Ingenuity Pathway Analysis (IPA), we identified upstream regu-
lators of  the 6 modules of  interconnected genes disturbed in muscle of  Smn–/–;SMN2 mice (Figure 10C). A 
complete list of  upstream regulators and their downstream targets is provided in Supplemental Table 4.
Our large network analyses, therefore, suggest that additional mechanistic investigations of  functional 
biological pathways are required to better understand the specific and direct benefits of  harmine in SMA 
muscle. Importantly, our bioinformatic analyses have uncovered several interesting molecular networks 
restored by harmine in SMA muscle that could have further implications for future development of  mus-
cle-specific therapies for SMA.
Discussion
Despite the tremendous recent advances in SMA gene therapy, this neuromuscular disorder remains incur-
able, and there is an urgent need for the development of  second-generation treatments that can be used in 
combination with SMN-dependent therapies (16–18). In this study, we evaluated and validated a strategy 
combining transcriptomics, proteomics, and drug repositioning to identify therapeutic compounds that have 
the potential to improve muscle pathology in SMA. An in-depth investigation of  one of  these drugs, harmine, 
Figure 5. Harmine, as predicted by CMap analyses, is able to reverse the expression of genes significantly upregulated in SMA muscle in several cellular 
models. (A–D) C2C12s, NSC-34s, SMA patient fibroblasts, and control fibroblasts were treated with 25, 35, or 50 μM of harmine for 48 hours. Expression of 
Clpx (A), Ppm1b (B), Tob2 (C), and Cdkn1a (D) was assessed by qPCR and compared with untreated cells. Data are shown as a scatter plot and are represented 
as mean ± SEM; n = 3 independent wells, 2-way ANOVA followed by uncorrected Fisher’s LSD, F = 182 (Clpx), F = 38.49 (Ppm1b), F = 78.17 (Tob2), F = 18.36 
(Cdkn1a), df = 32 for all, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Figure 6. Administration of harmine to SMA mice partially restores the expression of target genes, as predicted by CMap analyses. All treated animals 
received a daily dose of harmine (10 mg/kg, diluted in 0.9% saline) by gavage starting at P0. (A) qPCR analysis of Snrnp27, Gls, Aspm, and Mcm2 in triceps 
of P7 untreated and harmine-treated Smn–/–;SMN2 SMA mice and Smn+/–;SMN2 control littermates. Data are shown as a scatter plot and are represented 
as mean ± SEM, n = 4 animals per experimental group except for harmine-treated Smn+/–;SMN2 where n = 3, 2-way ANOVA followed by a Sidak’s multiple 
comparisons test, F = 25.77 (Snrnp27), F = 1.103 (Gls), F = 0.5143 (Aspm), F = 0.3992 (Mcm2), df = 11 for all, *P < 0.05, **P < 0.01. (B) qPCR analysis of Clpx, 
Ppm1b, Tob2, and Cdkn1a in triceps of P7 untreated and harmine-treated Smn–/–;SMN2 SMA mice and Smn+/–;SMN2 control littermates. Data are shown as 
a scatter plot and are represented as mean ± SD; n = 4 animals per experimental group except for harmine-treated Smn+/–;SMN2 where n = 3, 2-way ANOVA 
followed by a Sidak’s multiple comparisons test, F = 0.4275 (Clpx), F = 0.006960 (Ppm1b), F = 8.167 (Tob2), F = 1.195 (Cdkn1a), df = 11 for all, **P < 0.01.
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further supports our approach, since harmine restored several molecular, behavioral, and histological disease 
phenotypes in both cellular and animal models of  the disease.
Of  major importance, and to our surprise, we demonstrated that early SMN restoration via Pip6a-
PMO corrects most, if  not all, of  the transcriptomic and proteomic dysregulations in SMA muscle, high-
lighting the need for and likely benefit from early treatment intervention in SMA. It is important to note, 
however, that the Pip6a-PMO dose delivered to mice was very high and most likely higher than what would 
be expected in patients. Our pathway analyses revealed that many molecular functions that are dysregulat-
ed in SMA mice compared with WT mice and recovered by Pip6a-PMO have previously been implicated in 
the pathology of  SMA, including RNA metabolism and splicing, circadian regulation of  gene expression, 
ubiquitin pathways, regulation of  Rho protein signal transduction, and actin-binding pathways (51–54). 
Their normalization following SMN restoration further supports their involvement in SMA pathology.
Using the DE genes and proteins in SMA muscle compared with WT, we used a CMap perturbational 
data set to provide a list of  candidate drugs that could improve SMA pathology, some of  which had previ-
ously been evaluated in SMA, such as salbutamol (55). CMap analysis has been used to identify potential 
therapeutics for a range of  different conditions, such as skeletal muscle atrophy (56), osteoarthritic pain 
(57), lung adenocarcinoma (58), and kidney disease (59). CMap can also help establish prediction models 
for different adverse drug reactions and evaluate drug safety (60).
Figure 7. Administration of harmine to SMA mice improves weight and survival. All treated animals received a daily dose of harmine (10 mg/kg, diluted in 
0.9% saline) by gavage starting at P0. (A) Survival curves of untreated and harmine-treated Smn–/–;SMN2 mice. Kaplan-Meier survival curve is shown, with n = 
10 for untreated Smn–/–;SMN2 mice, n = 11 for harmine-treated Smn–/–;SMN2 mice, Log-rank (Mantel-Cox) test, *P = 0.0211. (B) Daily weights of untreated and 
harmine-treated Smn–/–;SMN2 mice. Data are represented as mean ± SEM; n = 10 for untreated Smn–/–;SMN2 mice, n = 11 for harmine-treated Smn–/–;SMN2 
mice, 2-way ANOVA followed by a Sidak’s multiple comparisons test, F = 95.70, df = 202, **P < 0.01, ****P < 0.0001. (C) Daily weights of untreated and 
harmine-treated Smn+/–;SMN2 mice. Data are represented as mean ± SEM; n = 13 for untreated Smn+/–;SMN2 mice, n = 15 for harmine-treated Smn+/–;SMN2 
mice, 2-way ANOVA followed by a Sidak’s multiple comparisons test, F = 2.897, df = 398. (D) Survival curves of untreated and harmine-treated Smn2B/– mice. 
Kaplan-Meier survival curves are shown, with n = 9 for untreated Smn2B/– mice, n = 7 for harmine-treated Smn2B/– mice, log-rank (Mantel-Cox) test, *P = 0.0221. 
(E) Daily weights of untreated and harmine-treated Smn2B/– mice. Data are represented as mean ± SEM, n = 9 for untreated Smn2B/– mice, n = 7 for harmine- 
treated Smn2B/– mice, 2-way ANOVA followed by a Sidak’s multiple comparisons test, F = 96.25, df = 287, *P < 0.05, ****P < 0.0001. (F) Daily weights of untreat-
ed and harmine-treated Smn2B/+ mice. Data are represented as mean ± SEM, n = 13 for untreated Smn2B/+ mice, n = 8 for harmine-treated Smn2B/+ mice, 2-way 
ANOVA followed by a Sidak’s multiple comparisons test, F = 206.3, df = 399, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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In this study, we chose to provide a more in-depth assessment of harmine, a drug predicted to restore DE 
genes and proteins in SMA muscle. Harmine is a β-carboline alkaloid and has various vasorelaxant, antiinflam-
matory, antimicrobial, analgesic, antioxidative, antimutagenic, antitumor, antidepressive, antiaddictive, and 
neuroprotective therapeutic effects (33, 61, 62). The pharmacological mechanisms involve several molecular 
targets including monoamine oxidase (MAO), serotonin 5-HT2A/C receptors, imidazoline I1/2 receptors, 
reactive oxygen species (ROS), dual specificity tyrosine phosphorylation–regulated kinase 1A (DYRK1A), 
GLT-1, and neurotrophic factors (33, 61, 62). In our study, one of the genes downregulated in SMA muscle 
compared with WT animals and increased by harmine was Snrnp27, a small nuclear RNP (snRNP) involved 
in pre-mRNA splicing (63), and SMN plays a canonical role in the assembly of snRNPs (64). Of note, while 
the observed change in Snrnp27 levels were small and further investigations are required to fully determine its 
biological significance, it was nevertheless observed in both SMA mice and healthy littermates, suggesting a 
Figure 8. Administration of harmine to SMA mice improves neuromuscular phenotypes. All treated animals received a daily dose of harmine (10 mg/kg, 
diluted in 0.9% saline) by gavage starting at P0. (A) Relative frequency of myofiber sizes in P7 untreated and harmine-treated Smn–/–;SMN2 and Smn+/–
;SMN2 mice. Data are shown as percentages, with n = 3 animals per experimental group and > 400 myofibers per experimental group. (B) Western blot and 
quantification of GLT-1/vinculin expression in the spinal cord of P7 untreated and harmine-treated Smn–/–;SMN2 and Smn+/–;SMN2 mice. Data are shown 
as a scatter plot and are represented as mean ± SEM; n = 3 for untreated and harmine-treated Smn+/–;SMN2 mice, n = 4 for untreated and harmine-treated 
Smn–/–;SMN2 mice, 2-way ANOVA followed by a Sidak’s multiple comparisons test, F = 35.01, df = 10, ****P < 0.0001. (C) Number of motor neuron cell 
bodies per ventral horn area in the spinal cord of P7 untreated and harmine-treated Smn–/–;SMN2 and Smn+/–;SMN2 mice. Data are represented as mean ± 
SEM n = 3 for untreated Smn+/–;SMN2 mice, n = 4 for harmine-treated Smn–/–;SMN2 and Smn+/–;SMN2 mice, n = 5 for untreated Smn–/–;SMN2 mice, 2-way 
ANOVA followed by a Tukey’s multiple comparisons test, F = 4.617, df = 12, *P < 0.05, **P < 0.01. Images are representative spinal cord ventral horn areas 
of untreated and harmine-treated Smn–/–;SMN2 mice. Total original magnification, ×20.
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Figure 9. RNA sequencing and pathway analysis reveals full rescue of 20% of dysregulated genes in SMA muscle following harmine administration. All 
treated animals received a daily dose of harmine (10 mg/kg, diluted in 0.9% saline) by gavage starting at P0. TAs were harvested at P7 from untreated and 
harmine-treated Smn–/–;SMN2 mice and WT animals and were processed for RNA sequencing. (A) Venn diagram representation of the differentially expressed 
(DE) genes based on the negative binomial distribution (DESeq2) in untreated Smn–/–;SMN2 mice versus untreated WT mice (blue), harmine-treated Smn–/–
;SMN2 mice versus untreated Smn–/–;SMN2 mice (purple), and untreated WT mice versus harmine-treated WT mice (orange). (B) Venn diagram representation 
of the DE genes based on the negative binomial distribution (DESeq2) in untreated Smn–/–;SMN2 mice versus untreated WT mice (blue), harmine-treated 
Smn–/–;SMN2 mice versus untreated Smn–/–;SMN2 mice (purple), and harmine-treated Smn–/–;SMN2 mice versus untreated WT mice (green). (C) Gene ontology 
(GO) biological processes enriched in genes DE in untreated Smn–/–;SMN2 mice versus untreated WT mice (blue), in harmine-treated Smn–/–;SMN2 mice versus 
untreated Smn–/–;SMN2 mice (purple), in untreated WT mice versus harmine-treated WT mice (orange), and in harmine-treated Smn–/–;SMN2 mice versus 
untreated WT (green). –LogP values for the enrichment are reported.
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potential direct and beneficial effect of harmine administration on Snrnp27 expression. Cdkn1a (or p21) was also 
identified as a potential molecular target of harmine. This mediator of cell cycle and DNA repair is reported 
to be upregulated in various SMA models (65–69). While we validated an upregulated expression of Cdkn1a 
in skeletal muscle of symptomatic SMA mice, harmine administration did not lead to its predicted downregu-
lation in vivo. Moreover, in our in vitro experiments, harmine actually increased Cdkn1a expression in certain 
cell types and at certain doses, further highlighting the importance of validating in situ predictions in relevant 
cell and animal models. Indeed, harmine did not demonstrate a predicted activity on all selected candidate 
reporter genes, and any observed activity varied between cell types and tissues. Given that the CMap analysis is 
primarily based on data from human cancer cell lines (MCF7, PC3, and HL60), distinct effects across cell types 
and tissues are to be expected. While harmine influenced a subset of the selected candidate reporter genes in 
the predicted direction, our RNA-seq analysis demonstrated that harmine does, in fact, normalize the expres-
sion of a large number of additional genes in skeletal muscle of SMA mice that are implicated in key muscle 
processes such as muscle structure development, muscle contraction, muscle system process, and muscle cell 
differentiation. Thus, our combined transcriptomics, proteomics, and CMap approach has not only identified 
genes that have previously been implicated in SMA pathology, but has also provided an extensive list of poten-
tially novel and relevant molecular targets for further mechanistic investigations and therapeutic development.
Harmine can cross the blood-brain barrier and has well-characterized neuroprotective properties, includ-
ing its ability to upregulate the expression of  GLT-1 in several neurodegenerative models (41, 42). We 
indeed showed that GLT-1 expression is significantly upregulated in the spinal cord of  SMA mice follow-
ing harmine administration, which could potentially counteract the reduced glutamate transporter activity 
that has previously been reported throughout the CNS of  SMA patients (70). In addition, we found that 
harmine significantly increased the number of  motor neurons in the spinal cord of  SMA animals. Howev-
er, it is unclear whether this prevention of  motor neuron loss is a cause or a consequence of  the improved 
weight and lifespan, simply reflects a delayed neurodegenerative process, and/or is associated with func-
tional improvements. Given that the extent of  motor neuron loss is quite similar between SMA mouse 
models of  varying severities, motor neuron health and function are most likely better correlated with disease 
progression than absolute number (71). Nevertheless, the fact that harmine exerted muscle and CNS effects 
makes it an interesting therapeutic option for SMA. However, it is important to note that harmine can also 
exert adverse effects such as the onset of  tremors (38–40), which we observed when dosing the intermediate 
Smn2B/– mouse model over a longer period of  time.
Notably, the diverse phenotypic changes observed in SMA mice occurred in spite of  harmine’s short 
half-life of  1–3 hours (72), suggesting that the observed restoration of  gene networks was sustained either 
through regulatory cascades and/or a self-reinforcement. Performing time-series or pseudotemporal analy-
ses of  the responding regulatory gene networks could elucidate the key reinforcing drivers. Although SMN 
protein levels were not increased and harmine treatment did not rescue the entire perturbed gene networks, 
the specificity of  harmine treatment in skeletal muscle is remarkable, with very few affected genes outside 
of  the perturbed gene networks. It is important to also consider that the benefits of  harmine in SMA mice 
may be due to direct effects in the target muscle tissue and/or indirect effects via improved phenotypes in the 
spinal cord and in additional pathologically affected peripheral tissues (e.g., heart, liver, pancreas; ref. 73) 
previously demonstrated to be functionally modulated by harmine (74–76) and not evaluated in the current 
study. Thus, while harmine itself  might not be the ideal SMA treatment due to its range of  pharmacological 
and adverse side effects (77), replicating harmine’s tissue-specific activities with more targeted compounds 
may prove an effective strategy for SMA therapeutic development.
To our knowledge, this is the first in-depth validation of  this combinatorial approach in SMA. We were 
able to show the strength and potential of  combining multiomics and drug repositioning to uncover poten-
tially novel therapeutic entities, which in this case was aimed at improving muscle health in SMA. Our work, 
thus, provides an invaluable list of  pharmacological compounds, upstream regulators, and molecular targets 
that can be evaluated for treatment of  SMA muscle pathology, as well as strong support for the use of  this 
combined multiomics and bioinformatic strategy.
Methods
Animals and animal procedures. WW mice (FVB/N and C57BL/6J; refs. 78, 79) were obtained from the Jackson 
Laboratory. The severe Smn–/–;SMN2+/– mouse model (22) was also obtained from The Jackson Laboratory 
(FVB.Cg-Smn1tm1Hung Tg[SMN2]2Hung/J). The moderate Smn2B/– mouse model (27, 80) was provided by 
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Lyndsay M. Murray (Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, United King-
dom). All experiments with live animals were performed at the Biomedical Services Building, University of  
Oxford. For all experiments, litters were randomly assigned at birth and whole litters composed of both sexes 
were used. Sample sizes were determined based on similar studies with SMA mice. For survival curves, the fol-
lowing humane endpoints, as defined in our Home Office Project Licence, were used. (a) For the Smn–/–;SMN2 
mice, animals were killed when they demonstrated either of the following clinical signs: hindlimb paralysis, 
immobility, inability to right (greater than 30 seconds), and greater than 15% weight loss. (b) For the Smn2B/– 
mice, animals were killed when they demonstrated either of the following clinical signs: hindlimb paralysis, 
immobility, inability to right (greater than 30 seconds), and greater than 18% weight loss.
The Pip6a-PMO and Pip6a-scrambled conjugates were both separately prepared in 0.9% saline solu-
tion and administered at a dose of  10 μg/g via an i.v. facial vein injection at P0 and P2.
Harmine hydrochloride (sc-295136, Insight Biotechnology Ltd., Santa Cruz Biotechnology Inc.) was 
dissolved in 0.9% saline and administered daily (10 mg/kg) by gavage.
Synthesis of  Pip6a peptide-PMO conjugates. The PMO sequence targeting ISS-N1 intron 7 (–10, –27) 
(5′-ATTCACTTTCATAATGCTGG-3′) and scrambled PMO (5′-TAC GTT ATA TCT CGT GAT AC-3′) 
were purchased from Gene Tools LLC (Corvallis).
The Pip6a Ac-(RXRRBRRXRYQFLIRXRBRXRB)-COOH peptide was manufactured by standard 
9-fluorenylmethoxy carbonyl chemistry, purified to > 90% purity by reverse-phase high-performance LC 
(HPLC) and conjugated to the 3′ end of  the PMO through an amide linkage. The conjugate was purified by 
cation exchange HPLC, desalted, and analyzed by MS. Pip6a peptide-PMO conjugates were dissolved in 
sterile water and filtered through a 0.22 μm cellulose acetate membrane before use.
Laminin staining of  skeletal muscle. TA muscles were fixed in 4% PFA overnight. Tissues were sectioned 
(13 μm) and incubated in blocking buffer for 2 hours (0.3% Triton-X, 20% FBS, and 20% normal goat 
serum in PBS; all from MilliporeSigma). After blocking, tissues were stained overnight at 4°C with rat 
anti-laminin (1:1000, L0663, Sigma-Aldrich) in blocking buffer. The next day, tissues were washed in PBS 
and probed using goat anti–rat IgG 488 secondary antibodies (1:500, AlexaFluor 488, Thermo Fisher Sci-
entific) for 1 hour. PBS-washed tissues were mounted in Fluoromount-G (Southern Biotech). Images were 
taken with a DM IRB microscope (Leica). Quantitative assays were performed in a blinded fashion on 3–5 
mice for each group and 5 sections per mouse. The area of  muscle fiber within designated regions of  the TA 
muscle sections was measured using Fiji (81).
Nissl staining of  spinal cord. Whole spinal cords were fixed in 4% PFA overnight and subsequently placed in 
a 30% sucrose solution (PBS). The lumbar areas of  the spinal cords were then flash-frozen in a 50:50 mixture 
of  OCT compound/30% sucrose, and 20 μm sections were cut. Sections were first rehydrated 40 minutes 
in PBS followed by a 10-minute permeabilization step in 0.1% Triton-X. Sections were washed in PBS and 
stained with Neurotrace 500/525 green fluorescent Nissl (1:500, N21480, Thermo Fisher Scientific). Sections 
were then washed in PBS, counterstained with DAPI, and mounted in Fluoromount-G (Southern Biotech). 
Images for quantification were taken with a DM IRB microscope (Leica). Motor neuron cell body counts 
in the ventral horn area of  the spinal cord were performed blindly on 3–5 mice per experimental group and 
5 sections per mouse using Fiji (81). Representative images were taken with an Olympus Fluoview FV1000 
confocal microscope and processed with Fiji (81).
qPCR. RNA was extracted from tissues and cells by either a RNeasy kit from Qiagen or by guanidin-
ium thiocyantate-acid-phenol-chloroform extraction using TRIzol Reagent (Invitrogen) as per manufactur-
er’s instructions. The same RNA extraction method was employed for similar experiments, and equal RNA 
amounts were used between samples within the same experiments. cDNA was prepared with the High Capacity 
Figure 10. Identification of molecular effectors involved in harmine activity in SMA muscle. (A) A gene functional network was built extracting gene inter-
actions from a Phenotypic Linkage Network (45) for the top 500 most differentially expressed (DE) genes (ordered by adjusted P value) in untreated Smn–/–; 
SMN2 mice versus untreated WT mice. Genes are represented as nodes and are colored by direction expression change in untreated Smn–/–;SMN2 mice 
versus untreated WT mice (left) and by direction of expression change in harmine-treated Smn–/–;SMN2 mice versus untreated Smn–/–;SMN2 mice (right). 
Gray nodes correspond to genes that are DE in the disease model (untreated Smn–/–;SMN2 mice versus untreated WT) mice but have not been restored by 
harmine treatment. (B) Top MGI enriched phenotypes for the 4 identified modules in the network (shown in A) that show reversed expression profile after 
harmine treatment. –LogP values for the enrichment are reported. (C) Ingenuity Pathway Analysis (IPA) tool was used to identify upstream regulators of the 
top 500 most differentially expressed genes in untreated Smn–/–;SMN2 mice versus untreated WT mice (shown in A). For each of the top 50 most significant 
upstream regulators shown (ordered on enrichment P values from left [most significant] to right [less significant]), we calculated the proportions of target 
genes within each of the 6 modules that are predicted to be regulated by the corresponding upstream regulator. Represented is a selected reduced list of 
regulators based on high proportion of target genes from Module 1 (muscle phenotypes) and Module 2 (glucose and lipid metabolism).
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cDNA Kit (Invitrogen) according to the manufacturer’s instructions. The cDNA template was amplified on 
a StepOnePlus Real-Time PCR Thermocycler (Invitrogen) with SYBR Green Mastermix from Applied Bio-
systems. qPCR data were analyzed using the StepOne Software v2.3 (Applied Biosystems). Primers used for 
qPCR were obtained from IDT, and sequences for primers were either self-designed or ready-made (Supple-
mental Table 5). Relative gene expression was quantified using the Pfaffl method (82), and primer efficiencies 
were calculated with the LinRegPCR software. We normalized the relative expression level of all tested genes 
in mouse tissue and cells to RNA polymerase II polypeptide J (PolJ) (83). For human cells, we ran a GeNorm kit 
(Primer Design) to identify ribosomal protein L13a (RPL13A) as a reference/housekeeping gene. Primers for 
RPL13A were from IDT (Assay ID, Hs.PT.58.47294843).
Cell culture. Both C2C12 (ATCC, CRL-1772; ref. 84) and NSC-34 (provided by Peter Claus, Hannover 
Medical School, Hannover, Germany; ref. 85) cell lines were maintained in growth media consisting of  
DMEM supplemented with 10% FBS and 1% penicillin/streptomycin (all from Invitrogen). The cells were 
cultured at 37°C with 5% CO2. C2C12 myoblasts were differentiated in DMEM containing 2% horse serum 
(HS) for 7 days to form multinucleated myotubes.
Human fibroblasts were obtained from Coriell Institute (SMA GM03813, control AG02261) and cul-
tured in DMEM, supplemented with 1% antibiotics/antimycotics and 20% FBS.
MTS assays. Cell viability and proliferation of  C2C12 and NSC-34 cells treated with harmine (sc-
202644, Insight Biotechnology Ltd., Sante Cruz Biotechnology Inc.) dissolved in DMSO (final concen-
tration 0.03%) were evaluated with a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-
fophenyl)-2H-tetrazolium (MTS) assay kit (Colorimetric). The measurements were made according to 
manufacturer’s instructions. Briefly, 10 μL of  MTS reagent was added directly to the wells, and cell plates 
were incubated at 37°C for a minimum of  1 hour. Absorbance was measured at 490 nm on a CLARIOstar 
plate reader (BMG LABTECH). Background absorbance was first subtracted using a set of  wells contain-
ing medium only, and it was then normalized to and expressed as a relative percentage of  the plate-averaged 
untreated control. To chemically induce apoptosis, cells were treated with 10 μM Staurosporine (Abcam).
Western blot. Freshly prepared radioimmunoprecipitation (RIPA) buffer was used to homogenize tissue and 
cells, consisting of 50 mM Tris (pH 8.8), 150mM NaCl, 1% NP-40, 0.5% Sodium Deoxycholate, 0.1% SDS, and 
complete mini-proteinase inhibitors (1 tablet per 10 mL extraction solution; Roche). Equal amounts of total pro-
tein were loaded, as measured by Bradford Assay. Protein samples were first diluted 1:1 with Laemmli sample 
buffer (Bio-Rad) containing 5% β-mercaptoethanol (MilliporeSigma) and heated at 100°C for 10 minutes. Next, 
samples were loaded on freshly made 1.5 mm 12% polyacrylamide separating and 5% stacking gel, and elec-
trophoresis was performed at 120 V for approximately 1.5 hours in running buffer. Subsequently, proteins were 
transferred from the gel onto to a polyvinylidene fluoride (PVDF) membrane (MilliporeSigma) via electroblot-
ting at 120 V for 60 minutes in transfer buffer containing 20% methanol. Membranes were then incubated for 2 
hours in Odyssey Blocking Buffer (Licor). The membrane was then probed overnight at 4°C with primary anti-
bodies (rabbit anti–GLT-1, 1:1000, Abcam, ab41621; mouse anti-vinculin, 1:200,000, Sigma-Aldrich, V9131) 
in Odyssey Blocking Buffer and 0.1% Tween-20. The next day, after three 10-minute washing steps with PBS, 
the membrane was incubated for 1 hour at room temperature with secondary antibodies conjugated to infrared 
dyes (goat anti–rabbit IgG [H + L], IRDye 800CW, LI-COR Biosciences, 827-08365; goat anti–mouse IgG [H 
+ L], IRDye 680RD, LI-COR Biosciences, 926-68070). Lastly, the membrane was washed again 3 times for 10 
minutes in PBS and visualized by scanning 700 nm and 800 nm channels on the LI-COR Odyssey CLx infrared 
imaging system (LI-COR) for 2.5 minutes per channel. The background was subtracted, and the signal of pro-
tein of interest was divided by signal of the housekeeping protein or total protein, per sample.
Proteomic analysis. Proteomic analyses were performed using a LC-MS–based method. High-resolution 
isoelectric focusing (HiRIEF) was used at the peptide level in the 3.7–5.0 pH range. Two tandem mass tags 
(TMTs, chemical labels) were used for MS-based quantification and identification of  proteins. The data 
were median normalized based on peptide ratio. Among a total of  9798 potentially detectable proteins, 
most (8152 proteins) were identified in all samples/groups.
The limma R package was used for differential expression analysis, whereby DE proteins were defined 
by FDR < 0.05. GO enrichment analysis of  proteomic data were executed using topGO R function, and 
adjusted P values were found for multiple testing following a Benjamini-Hochberg correction. For PCA, we 
used the prcomp R function on the normalized expression data.
Microarray analysis. RNA was extracted by guanidinium thiocyantate-acid-phenol-chloroform extraction 
using TRIzol Reagent (Invitrogen) as per manufacturer’s instructions. GeneChip Mouse Transcriptome Assay 
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1.0 arrays were used (Affymetrix core facility, Karolinska Institute) with 100 ng of  RNA per sample. Anno-
tations for the Mouse Transcript Array 1.0 at the transcript level were obtained from the Affymetrix website 
(http://www.affymetrix.com/products_services/arrays/specific/mo_trans_assay.affx#1_4). We performed 
background correction and RMA normalization at the probe level using oligo R package. We summarized the 
data in ensemble transcript IDs using the average. The total number of  ensemble transcript IDs was 93,594, 
corresponding to 37,450 genes. For differential expression analysis, we used the limma R package and consid-
ered a transcript DE if  their FDR < 0.05. A gene was considered DE if  at least 1 of  the associated transcripts 
was DE. GO enrichment analysis was performed in R using the topGO function as described for proteomic 
data. For PCA, we used the prcomp R function on the RMA normalized gene expression data at the gene 
level (for comparison with proteomic data).
Combined analysis of  proteomic and transcriptomic data. To measure the similarity between gene expression pro-
files, we used the Ward hierarchical clustering on the Euclidean distance of 1 – r (where r is the Pearson correlation 
between samples). To compare the 2 omics readouts, proteomic and transcriptomic data were scaled (transformed 
to Z-score values), followed by a PCA showing that PC1 divides the data at the transcript and protein levels. Using 
the kill.pc function in the swamp R package, we extracted a new expression matrix where the variance given by 
PC1 had been removed. Finally, we performed hierarchical clustering analysis on the new expression matrix.
RNA-seq analysis. RNA was extracted using a RNeasy Microarray Tissue Mini Kit from Qiagen. Lysis 
and homogenization were performed using QIAzol Lysis Reagent. cDNA synthesis and RNA-seq library 
construction were performed at the Oxford Genomics Centre using poly(A) enrichment of  the mRNA 
(mRNA-seq) and HiSeq 4000 Systems for sequencing. All samples passed quality control. For differential 
expression analysis, we used DESeq2 on genes expressed across all samples (15,523 genes) after removal 
of  1 outlier (harmine-treated Smn–/–;SMN2 sample 1). We considered a gene DE at FDR < 0.05. For GO 
enrichment analysis, we used topGO R function and adjusted P values for multiple testing following a 
Benjamini-Hochberg correction. For mouse phenotype enrichment analysis, we downloaded phenotypes 
from the Mouse Genome Database, Mouse Genome Informatics, The Jackson Laboratory (http://www.
informatics.jax.org) and used an in-house script to correct for the background set of  expressed genes.
Differential isoform expression analysis. Transcript counts were first obtained using Salmon software 
v.0.11.2 (86). Differential isoform usage was then analyzed using edgeR package (87), considering an iso-
form as DE when the adjusted P value in the comparison between samples was below 0.05.
Gene functional network and clustering method. A gene functional network was built by extracting interac-
tions from a phenotypic linkage network (50) for the top 500 most DE genes in Smn–/–;SMN2 mice versus 
WT mice. To identify modules of  highly interconnected genes in the network, we employed “cluster_lou-
vain” function in “igraph” R package (88). This function implements the multilevel modularity optimi-
zation algorithm (89, 90) where, at each step, genes are reassigned to modules in a greedy way, and the 
process stops when the modularity does not increase in a successive step.
Upstream regulators. IPA (QIAGEN; www.qiagenbioinformatics.com) was used to identify the top 50 
upstream regulators for the top 500 most DE genes in Smn–/–;SMN2 mice versus WT mice. A reduced list 
of  regulators was identified based on enrichment of  their target genes within the 4 modules in the network 
that are restored upon harmine treatment.
GTEx tissue enrichment analysis. GTEx V7 tissue gene expression profiles were downloaded from gtex-
portal.org. For each tissue, we averaged the gene expression profiles across individuals, and we then identi-
fied tissue-specific genes as those with a fold change > +5 calculated for the expression in one tissue com-
pared with all other tissues. Gene enrichment P values (hypergeometric test) were computed for the overlap 
between the identified tissue-specific gene sets and our sets of  DE genes.
CMap analysis. Ensembl transcript identifications (IDs) from mice were mapped to human probe 
IDs (HG-U133A) using biomaRt (Ensembl transcript ID mus musculus → Ensembl gene ID mus muscu-
lus → ortholog_one2one → Ensembl gene ID homo sapiens → HG-U133A ID). We compared the iden-
tified disease and Pip6a-PMO signatures (top 500 upregulated and top 500 downregulated transcripts/
proteins) to 6100 drug instances contained at CMap (Build 02, https://www.broadinstitute.org/connectiv-
ity-map-cmap). Each instance corresponds to a drug response (treatment versus vehicle control) in a partic-
ular cell line and covers up to 1230 drugs across mainly 3 human cell lines (MCF7 = 3095 instances, PC3 
= 1741 instances, HL60 = 1229 instances, ssMCF7 = 18 instances, and SKMEL5 = 17 instances). We used 
the proven CMap algorithm; however, it is important to note that, although some improvements have been 
proposed, they have not been systematically evaluated (91). Briefly, each subset of  up- and downregulated 
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genes is compared with each instance by taking into account the ranked differences using a nonparametric 
rank test (Kolmogorov-Smirnov statistic). For each instance, a connectivity score (ranging from +1 to –1) 
represents the relative strength in which a drug induced (+ 1) or reversed (–1) a given gene signature, while 
zero indicates a random distribution of  up- and downregulated genes in the ranked response of  a drug.
Data availability. The data sets generated during and/or analyzed during the current study are included 
in this published article (and its supplementary material).
The expression data discussed in this publication have been deposited in NCBI’s Gene Expression 
Omnibus (92) and are accessible through GEO Series accession no. GSE150510 (https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE150510) and GSE150517 (https://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE150517) for RNA-Seq and microarray data, respectively.
Associated raw data for the proteomics analysis can be found in the Proteomics Source Data file.
Statistics. All nonbioinformatic statistical analyses were done with the most Graphpad Prism software 
(version 8.4.2). When appropriate, a Student’s unpaired 2-tailed t-test, a 1-way ANOVA, or a 2-way ANO-
VA was used. Post hoc analyses used are specified in figure legends. Outliers were identified via the Grubbs’ 
test. For the Kaplan-Meier survival analysis, the log-rank test was used, and survival curves were consid-
ered significantly different at P < 0.05.
Study approval. Experimental procedures were authorized and approved by the University of  Oxford 
ethics committee and UK Home Office (current project license PDFEDC6F0, previous project license 
30/2907) in accordance with the Animals (Scientific Procedures) Act 1986.
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